Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 16:14 ET | Source: Phoenix Molecular Designs

Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer

Phoenix Molecular Designs dosed the first patient in Dauntless-1, a Phase 2 trial of PMD-026 and fulvestrant for RSK2-high metastatic breast cancer.